Posted by Michael Wonder on 29 Jul 2020
Nabriva receives European approval for Xenleta (lefamulin) for treatment of community-acquired pneumonia
28 July 2020 - Xenleta represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years.
Nabriva Therapeutics announced today that the European Commission has issued a legally binding decision for approval of the marketing authorisation application for Xenleta (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults following a review by the EMA.
The EMA approval of Xenleta in CAP patients when it is considered inappropriate to use antibacterial agents that are commonly recommended for initial treatment or when these agents have failed paves the way for the launch of Xenleta across Europe.
